Botensilimab
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Botensilimab is a novel monoclonal antibody designed for the treatment of various types of cancer. It is currently under investigation in clinical trials for its efficacy and safety in treating solid tumors and other malignancies. Botensilimab functions as an immune checkpoint inhibitor, targeting specific proteins on the surface of T cells to enhance the body's immune response against cancer cells.
Mechanism of Action[edit | edit source]
Botensilimab works by inhibiting the interaction between immune checkpoint proteins, such as CTLA-4 and PD-1, and their ligands. This inhibition prevents the downregulation of T cell activity, thereby enhancing the immune system's ability to recognize and destroy cancer cells. By blocking these checkpoints, Botensilimab effectively "releases the brakes" on the immune system, allowing for a more robust anti-tumor response.
Clinical Development[edit | edit source]
Botensilimab is currently in various phases of clinical trials. Early-phase studies have shown promising results in terms of tumor shrinkage and patient survival rates. The drug is being tested in combination with other therapies, such as chemotherapy and radiotherapy, to evaluate its synergistic effects.
Side Effects[edit | edit source]
As with other immune checkpoint inhibitors, Botensilimab can cause a range of side effects, primarily due to increased immune activity. Common side effects include fatigue, rash, and diarrhea. More severe immune-related adverse events can occur, such as pneumonitis, hepatitis, and colitis.
Regulatory Status[edit | edit source]
Botensilimab is not yet approved by major regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is available only through clinical trials.
Research and Future Directions[edit | edit source]
Ongoing research is focused on identifying biomarkers that predict response to Botensilimab, optimizing dosing regimens, and exploring its use in combination with other immunotherapies. The potential for Botensilimab to treat a wide range of cancers makes it a significant focus of current oncological research.
Also see[edit | edit source]
Template:Immunotherapy sidebar
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
